Thu, Apr 17, 2014, 3:20 PM EDT - U.S. Markets close in 40 mins.

Recent

% | $
Quotes you view appear here for quick access.

Nordstrom Inc. Message Board

jgmtruth 242 posts  |  Last Activity: 3 hours ago Member since: Feb 21, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Hey Doc. how are you as for IDRA In this market its hard enough with big names such as CELG,GILD and PCYC .IMO it will take some time before early clinical stage companies get any respect .Also the Baker boys got some bad press from the street old Adam F."The Recent Performance of 'Baker Brother Biotech Stocks' is Awful" That kind of news doesn't help small co.like IDRA at all.JMHO.All of you have a great weekend .

    Sentiment: Hold

  • Reply to

    no rhyme or reason

    by jgmtruth Apr 4, 2014 11:53 AM
    jgmtruth jgmtruth Apr 4, 2014 5:08 PM Flag

    Then you must remember the Bio Pharma Group nice bunch of guys..

    Sentiment: Strong Buy

  • Reply to

    no rhyme or reason

    by jgmtruth Apr 4, 2014 11:53 AM
    jgmtruth jgmtruth Apr 4, 2014 1:03 PM Flag

    Well no need wondering its down over 100.Pure manipulation by the powers that be.

    Sentiment: Strong Buy

  • jgmtruth by jgmtruth Apr 4, 2014 11:53 AM Flag

    One huge smackdown on all stocks.One word baffling.

    Sentiment: Strong Buy

  • jgmtruth jgmtruth Mar 28, 2014 9:53 AM Flag

    Persistent lymphocytosis with ibrutinib does not indicate early relapse

    By: BIANCA NOGRADY, Oncology Report Digital Network

    Persistent lymphocytosis lasting more than 12 months in patients with chronic lymphocytic leukemia undergoing treatment with ibrutinib is not associated with a greater likelihood of early relapse.

    A prospective observational study in 85 relapsed or refractory patients with chronic lymphocytic leukemia treated with ibrutinib showed lymphocytosis occurred in 77% in patients, persisting at 12 months in 20% of patients.

    Dr. Jennifer A. Woyach of Ohio State University, Columbus, and her colleagues found no significant differences in progression-free survival between patients who responded to treatment but showed persistent lymphocytosis, and those with a partial or complete response to treatment without lymphocytosis.

    They also found no significant differences in gene expression profiles in persistent lymphocytosis, suggesting that the lymphocytosis most likely represented the movement of quiescent cells (Blood 2014;123:1810-17).

    Two authors were unpaid consultants for, three were paid consultants for, and two were employees of Pharmacyclics. One author received research funding from Janssen. The study was funded by the Four Winds Foundation, the Leukemia and Lymphoma Society, and several other organizations. Ibrutinib was provided by Pharmacyclics for in vitro experiments.

    Sentiment: Strong Buy

  • Dallas, Texas 03/28/2014 (FINANCIALSTRENDS) – Morgan Stanley has assumed coverage on Pharmacyclics, Inc (NASDAQ:PCYC) shares of Pharmacyclics (NASDAQ:PCYC) in a report released on Wednesday, Stock. The firm has assigned an “equal weight” rating and a price target of $120.00 on the stock. Recently, numerous other analysts have commented on the company stock. Analysts at the Roth Capital firm have upped their price target on Pharmacyclics, Inc (NASDAQ:PCYC) shares to $183.00 in the research note on 24 February. Separately, Zacks analysts have reiterated their neutral rating on Pharmacyclics, Inc (NASDAQ:PCYC) shares in the research note on 24 February.


    They have now set a price target of $159.00 on the stock. Finally, the analysts at Deutsche Bank have raised their PT on Pharmacyclics, Inc (NASDAQ:PCYC) shares from $170.00 up to $180.00 in the research note on 21 February. They have now set a rating of “buy rating on the company stock. Four research analysts have rated the Pharmacyclics, Inc (NASDAQ:PCYC) stock with a “hold” rating and 8 have given a “buy” rating to the company. Currently, the average rating on Pharmacyclics, Inc (NASDAQ:PCYC) is a “buy” and the average PT is $156.25.

    Pharmacyclics (NASDAQ:PCYC) last issued the company’s quarterly-earnings data on 20 February. It reported earnings per share of $0.95 for the quarter, which topped the average analysts’ projections of beating of $0.67 by $0.28. Pharmacyclics, Inc (NASDAQ:PCYC) had revenue of $123.60M for the quarter, in comparison to the average projection of $85.69 million. On an average, analysts project that Pharmacyclics, Inc (NASDAQ:PCYC) will post earnings per share of $0.11 for the current financial year.

    Pharmacyclics, Inc (NASDAQ:PCYC) is a clinical stage bio pharmaceutical company that is focused on the development & commercializing of the small-molecule drugs used to treat cancer & immune mediated diseases. Its clinical development & product candidates are the small-molecule enzyme-inhibitors that are designed to target the biochemical pathways that are involved in human diseases.

    Sentiment: Strong Buy

  • JPMorgan’s Geoff Meacham and team explain why fears of a biotech bubble are unfounded:

    After two years of dramatic outperformance, concerns about valuation and a “biotech bubble” have emerged. We believe that the sector remains broadly attractive from a valuation/pipeline/growth perspective, particularly in large cap. Notably, the average 3-year revenue and EPS CAGR for the top 10 biotechs (market cap) is 4.5X and 3X that of the S&P500, yet the P/E/G on 2015-2016 forecasts for biotech is ~0.7 versus the S&P at ~1.4. Regarding the industry pipeline, product cycles are very long in biotech ( 10 years) and dozens of major launches are occurring or are about to occur ([Gilead's] Sovaldi, [Biogen Idec's] Tecfidera, Imbruvica, Pomalyst, [Celgene's] Otezla, [Regeneron's] Eylea, Kalydeco, Xtandi, Linzess asfotase alfa, Vimizim, idelalisib, evolocumab, alirocumab, etc.). In addition, we estimate that at least 50+ compounds/label expansions that have some level of derisking are largely unaccounted for in Street models. Admittedly, companies with earlier-stage pipelines that haven’t been fully de-risked are being awarded a higher probability of clinical success, but drug development has become more efficient, particularly for orphan drugs. The recent concern on pricing for Gilead’s Sovaldi has caused much anxiety; at the end of the day, the benefit/risk and cost/benefit profile remains quite striking and we doubt that the recent Congressional inquiry would lead to an “innovation tax” (i.e., forced material discounts).

    Sentiment: Strong Buy

  • jgmtruth by jgmtruth Mar 22, 2014 10:49 AM Flag

    How are things going along with the cancer situation with your mother?I hope all is well.I wish you and your family all the best..godspeed my friend.

  • Reply to

    Holdor buy more if you can

    by sdotmollard Mar 21, 2014 4:00 PM
    jgmtruth jgmtruth Mar 21, 2014 4:07 PM Flag

    It was very impressive i must agree given the market conditions over all sectors..Have a good weekend.

    Sentiment: Strong Buy

  • Reply to

    Sure looks like short covering here.

    by bearofbleecker Mar 21, 2014 10:47 AM
    jgmtruth jgmtruth Mar 21, 2014 2:29 PM Flag

    You mean a search for a cancer cure will be over or any kind of cure for any incurable diseases .The research is very expensive and you would never be able to recoup the cost .

    Sentiment: Strong Buy

  • Reply to

    Sure looks like short covering here.

    by bearofbleecker Mar 21, 2014 10:47 AM
    jgmtruth jgmtruth Mar 21, 2014 1:47 PM Flag

    It's like getting kicked when you are already down on the floor..

    Sentiment: Strong Buy

  • jgmtruth jgmtruth Mar 21, 2014 1:21 PM Flag

    the selling of good stocks like PCYC because of a LETTER from lawmaker to GILD.. regret of selling will be felt later, upside huge.IMO .I just read this about J$J..Johnson & Johnson is the big, diversified player of the pharma space, but that doesn't make it a sleepy conglomerate, argues Motley Fool analyst David Williamson. Its pharmaceutical division is cranking out consistent double-digit growth rates thanks to strong products like Zytiga in prostate cancer and megablockbuster Remicade, and the success continues with recent approval for Imbruvica, a blood cancer drug with expected peak sales in the $6 billion-$7 billion range. Its medical device business is set for growth following the massive Synthes acquisition, and J&J is wisely selling off lower-margin diagnostics. This is a steady stock with a strong dividend, but a pharma division firing on all cylinders provides meaningful upside for investors.

    Sentiment: Strong Buy

  • Reply to

    Sure looks like short covering here.

    by bearofbleecker Mar 21, 2014 10:47 AM
    jgmtruth jgmtruth Mar 21, 2014 11:14 AM Flag

    i've never seen so many oversold stocks in one day.

    Sentiment: Strong Buy

  • Reply to

    Wells Fargo this am

    by sdotmollard Mar 21, 2014 9:26 AM
    jgmtruth jgmtruth Mar 21, 2014 10:08 AM Flag

    reiterated an Outperform rating on Pharmacyclics (NASDAQ: PCYC). IMS released scripts data for the week ending March 14, including an adjustment for mail channel overstatement announced yesterday. The correction was applied to March 14 data.

    "Including the 12.7% and 14.6% reductions in TRx and NRx (based on IMS's correction), TRx and NRx were 523 vs. 547 (4.4%) and 322 vs. 364 (11.5%), respectively. The two prior weeks were 4.8%, +6.5% for TRx and 2.2% and 2.8% for NRx," said analyst Matthew J. Andrews. "If we add back the 12.7% and 14.6% IMS reductions (for 3/14 data) in order to normalize for the prior week's TRx and NRx and ascertain general week-on-week trends, TRx were 589 (+8%) and NRX were 369 (+1.4%), respectively, indicating Imbruvica was able to reverse the prior week's decrease. With this caveat in mind, this normalized TRx would represent the highest number of TRx scrips to date (week ended 2/28/14 TRx was 575). In order to extrapolate a more detailed and accurate projection for our Q1 2014 Imbruvica sales estimate, we await IMS Health's full correction for all weeks in Q1 (which will be issued on 3/28/14). FactSet consensus estimate is currently ~$41M."

    "With IMS Health's issuing its Q4 2013/Q1 2014 corrections next Friday we will be able to project a more accurate Q1 Imbruvica revenue run rate. When adding back the TRx correction of 12.7%, the general trend for Imbruvica TRx/NRx is positive (+8% weekonweek) and TRx are the highest to date, suggesting that peak penetration has not yet occurred in the U.S. R/R CLL and MCL markets. We believe this scrips update is likely to be positively received and with shares finding support intraday on 3/20/14 at the 200day moving average (~$117) we believe shares are likely to appreciate\ during 3/21/14. Our long-term thesis on PCYC is unchanged," he added.

    Sentiment: Strong Buy

  • jgmtruth jgmtruth Mar 20, 2014 4:53 PM Flag

    That chart looks almost like PCYC today..

  • jgmtruth jgmtruth Mar 20, 2014 4:52 PM Flag

    http://finance.yahoo.com/q?s=^YHOh784

  • Somaiya wrote that his survey of 30 doctors treating more than 1,600 CLL patients "highlighted rapid transition of the CLL market to newer oral drugs, in particular PCYC's Imbruvica," which was launched by Pharmacyclics and Johnson & Johnson (JNJ) in November and approved for CLL last month.
    He wrote that the doctors generally thought Imbruvica is better than idelalisib

    Sentiment: Strong Buy

  • 19 Mar 2014 Prescription drugs that are on the market have all attained stringent approval by the Food and Drug Administration (FDA), but not all of the drugs are prescribed in manners that adhere to FDA authorization.

    Off-label prescribing — the act of prescribing a drug for uses, or in dosages, other than the ones stated on its label — is a rampant phenomenon that relies on physicians’ judgment, patients’ will and pharmaceutical companies’ information.

    In the realm of oncology drugs, off-label prescribing is even more common than in the world of prescription drugs as a whole. Between 50 percent and 75 percent of oncology drugs are being administered off-label, according to the National Comprehensive Cancer Network, whose guidelines and statements are considered to be standard consensus in oncology.

    Imbruvica — an oral treatment first approved in November 2013 for mantle-cell lymphoma (MCL), which is a rare and aggressive type of immune system cancer that hits 3,900 people in the U.S. per year — was once in the mix, but is now expected to be moving away from off-label use, in light of its second FDA approval for treatment of chronic lymphocytic leukemia (CLL), a more common type of blood cancer that hits 15,720 people in the U.S. per year.

    Between its first FDA approval and this second approval on Feb. 12 of this year, an estimated 35 percent of Imbruvica’s sales were for off-label usage in CLL treatment — and this was while the drug was in the early stages of clinical trials for CLL — according to Deutsche Bank analyst Robyn Karnauskas. Back in January, Karnauskas had anticipated Imbruvica’s off-label sales to increase beyond 35 percent, on the heels of positive results from a late-stage CLL clinical trial.

    For Imbruvica, off-label usage for CLL stemmed from initial belief that the first approval would have been for CLL, not the more rare MCL, and was further boosted by favorable CLL clinical trial results.

    This is not always the case behind off-label oncology prescriptions. The driver often is practicality. Some cancers are especially rare, making it difficult for pharmaceutical companies to obtain enough subjects to perform the clinical trials necessary to gain FDA approval.

    Desperate patients are acutely aware that a potential treatment may never gain FDA approval, and in oncology, early access to a treatment can be life saving. Patients often are willing to test new regimens that may benefit them, the drugs are there — albeit for a different patient demographic, type of illness or dosage — and physicians are legally able to prescribe as they see fit. This creates an environment especially conducive to off-label usage.

    “While there is good scientific rational and clinical evidence for efficacy and safety in many indications beyond the label, use will be dependent upon the conversation between the physician and patient,” said Gregory Wade, an analyst with Wedbush Securities’ San Francisco office. “Physicians who prescribe drugs off-label possess the training and knowledge to do so safely.”

    Even so, the practice undermines FDA standards, which stress rigorous studies and evidence to ensure safety and efficacy for each specific situation. By bypassing a complete FDA review, there always remains the possibility of inefficacy or harm from off-label use, experts say.

    Off-label usage also poses potential benefits for pharmaceutical companies. Whether or not their drug is being clinically tested for the use for which it is being prescribed off-label, they benefit from the additional sales generated by a wider range of patients. Pharmaceutical companies whose drugs are not in clinical trials for additional uses stand to benefit even more. They can bypass the time and monetary costs of running clinical trials for off-label usage.

    Given the potential incentives held by off-label usage for pharmaceutical companies, there is a caveat to the practice. Off-label prescribing — the physician side of the practice — is legal, but off-label promotion by pharmaceutical companies is illegal.

    Pharmaceutical companies must maneuver a fine line between providing physicians with information about all possible treatments of a drug and promoting the drug for such off-label usage.

    “Off-label marketing isn’t the norm and evidence suggests that companies spend a great deal of effort in compliance,” analyst Wade said.

    Those that do engage in off-label marketing, though in the minority, face heavy fines. In September 2008, and January and September 2009, pharmaceutical companies Cephalon, Inc., Eli Lilly & Co. and Pfizer, Inc. each paid steep fines for off-label promotion, to the tune of $425 million, $1.4 billion and $2.3 billion, respectively.

    Pharmacyclics’ senior director of public relations and corporate communications, Manisha Pai, said in an interview: “We don’t promote or track off-label use, but our sales force ensures that physicians are knowledgeable about all the components of the drug.”

    Even without the role of off-label promotion, an estimated 20 percent of prescription drug sales are off-label, according to liability firm, Gilbert, LLP.

    In the Feb. 12 conference call announcing Imbruvica’s second FDA approval, executive vice president of Pharmacyclics’ sales and marketing, Paula Boultbee, addressed the matter of off-label Imbruvica use in CLL patients, stating, “We don’t know very much about the patients that have been treated in spontaneous fashion by physicians without the label … but we do expect that with Imbruvica approved in the CLL space, it (off-label use) will change quite dramatically.”

    Imbruvica’s approval for CLL treatment eliminates room for off-label prescribing in that specific population; but that does not mean that Imbruvica might not be prescribed off-label for another demographic, such as elderly patients who have not undergone chemotherapy, or for another type of cancer, such as Waldenstrom’s — a rare type of blood cancer that affects 1,500 people in the U.S. annually.

    “As we don’t track off-label use, I can’t really speculate about whether Imbruvica’s off-label use in relation to CLL treatment has diminished, but I can say that Imbruvica is being tested in many clinical trials for other uses at this time,” Pai said.

    Sentiment: Strong Buy

  • CANV - 4.925 % CBIS -2.45% GRNH -7.06% GRNH -.49% GWPRF- .50% HEMP -2.54% HSCC- 3.95% MJNA - 3.00% NVLX - 7.30% RIGH - 14.30% TRTC - 8.25% Just one of those days ..PHOT STRONG BUY....IMO

    Sentiment: Strong Buy

  • DETROIT — Marijuana can be used to relieve post-traumatic stress disorder in Michigan, the first new condition since voters approved pot for medicinal use in 2008.

    The head of a state agency that oversees the #$%$ program says he's following the recommendation of a review panel but he still has concerns. Steve Arwood signed an order Friday.

    Arwood says using marijuana for PTSD means the Michigan program now is moving into mental health. Marijuana typically has been used to relieve the side effects of cancer, glaucoma, HIV, hepatitis C and a few other conditions.

    PTSD is considered a mental health condition linked to a terrifying event.

    Michigan users of #$%$ need certification from a doctor and a card from the state. More than 100,000 people have cards.

    Sentiment: Strong Buy

JWN
60.70-0.76(-1.24%)3:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.